Provectus Biopharmaceuticals, Inc. PVCT
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -62.50% | 30.29% | |||
| Gross Profit | 62.50% | -30.29% | |||
| SG&A Expenses | -20.16% | 21.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.16% | 21.89% | |||
| Operating Income | 31.16% | -21.89% | |||
| Income Before Tax | 24.00% | -11.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.00% | -11.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -40.95% | 275.00% | |||
| Net Income | 23.86% | -10.77% | |||
| EBIT | 31.16% | -21.89% | |||
| EBITDA | 31.18% | -21.89% | |||
| EPS Basic | 25.81% | -10.71% | |||
| Normalized Basic EPS | 31.58% | -18.75% | |||
| EPS Diluted | 25.81% | -10.71% | |||
| Normalized Diluted EPS | 31.58% | -18.75% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||